Sian Fereday

Sian Fereday

UNVERIFIED PROFILE

Are you Sian Fereday?   Register this Author

Register author
Sian Fereday

Sian Fereday

Publications by authors named "Sian Fereday"

Are you Sian Fereday?   Register this Author

35Publications

1669Reads

30Profile Views

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Authors:
Peter F Rambau Robert A Vierkant Maria P Intermaggio Linda E Kelemen Marc T Goodman Esther Herpel Paul D Pharoah Stefan Kommoss Mercedes Jimenez-Linan Beth Y Karlan Aleksandra Gentry-Maharaj Usha Menon Susanna Hernando Polo Francisco J Candido Dos Reis Jennifer Anne Doherty Simon A Gayther Raghwa Sharma Melissa C Larson Paul R Harnett Emma Hatfield Jurandyr M de Andrade Gregg S Nelson Helen Steed Joellen M Schildkraut Micheal E Carney Estrid Høgdall Alice S Whittemore Martin Widschwendter Catherine J Kennedy Frances Wang Qin Wang Chen Wang Sebastian M Armasu Frances Daley Penny Coulson Micheal E Jones Micheal S Anglesio Christine Chow Anna de Fazio Montserrat García-Closas Sara Y Brucker Cezary Cybulski Holly R Harris Andreas D Hartkopf Tomasz Huzarski Allan Jensen Jan Lubiński Oleg Oszurek Javier Benitez Fady Mina Annette Staebler Florin Andrei Taran Jana Pasternak Aline Talhouk Mary Anne Rossing Joy Hendley Robert P Edwards Sian Fereday Francesmary Modugno Roberta B Ness Weiva Sieh Mona A El-Bahrawy Stacey J Winham Jenny Lester Susanne K Kjaer Jacek Gronwald Peter Sinn Peter A Fasching Jenny Chang-Claude Kirsten B Moysich David D Bowtell Brenda Y Hernandez Hugh Luk Sabine Behrens Mitul Shah Audrey Jung Prafull Ghatage Jennifer Alsop Kathryn Alsop Jesús García-Donas Pamela J Thompson Anthony J Swerdlow Chloe Karpinskyj Alicia Cazorla-Jiménez María J García Susha Deen Lynne R Wilkens José Palacios Andrew Berchuck Jennifer M Koziak James D Brenton Linda S Cook Ellen L Goode David G Huntsman Susan J Ramus Martin Köbel

J Pathol Clin Res 2018 10 21;4(4):250-261. Epub 2018 Sep 21.

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cjp2.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174617PMC
October 2018

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Gynecol Oncol 2018 08 26;150(2):239-246. Epub 2018 May 26.

Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.05.020DOI Listing
August 2018

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Mayo Clin Proc 2018 03;93(3):307-320

Department of Health Sciences Research, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2017.10.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870793PMC
March 2018

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.

J Clin Oncol 2017 Apr 13;35(12):1274-1280. Epub 2017 Feb 13.

Elizabeth L. Christie, Sian Fereday, Ken Doig, Sarah-Jane Dawson, and David D.L. Bowtell, Peter MacCallum Cancer Centre, Melbourne; Elizabeth L. Christe, Ken Doig, Sarah-Jane Dawson, David D.L. Bowtell, University of Melbourne, Melbourne, Victoria; and Swetansu Pattnaik and David D.L. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4627DOI Listing
April 2017

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gynecol Oncol 2016 Sep 18;142(3):458-64. Epub 2016 Jul 18.

The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia; Department of Gynecological Oncology, Westmead Hospital, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.06.023DOI Listing
September 2016

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Mol Cancer Ther 2015 Jun 7;14(6):1495-503. Epub 2015 Apr 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0039DOI Listing
June 2015

Whole-genome characterization of chemoresistant ovarian cancer.

Nature 2015 May;521(7553):489-94

1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia [4] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK [5] Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14410DOI Listing
May 2015

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.

Clin Cancer Res 2015 Feb 14;21(3):652-7. Epub 2014 Nov 14.

Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/01/
Web Search
http://clincancerres.aacrjournals.org/content/21/3/652.full.
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-2497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338615PMC
February 2015

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Clin Cancer Res 2014 Dec 14;20(24):6618-30. Epub 2014 Oct 14.

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia. University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1292DOI Listing
December 2014

Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).

Gynecol Oncol 2014 Apr;133(1):16-22

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258140004
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2014.01.030DOI Listing
April 2014

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Lancet Oncol 2013 Aug 9;14(9):853-62. Epub 2013 Jul 9.

Division of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70253-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006367PMC
August 2013

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

J Pathol 2010 May;221(1):49-56

Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.2696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262968PMC
May 2010